Show simple item record

dc.contributor.authorde Kuijper, Gerda
dc.contributor.authorde Haan, J
dc.contributor.authorDeb, Shoumitro
dc.contributor.authorShankar, Rohit
dc.date.accessioned2022-12-20T11:56:50Z
dc.date.available2022-12-20T11:56:50Z
dc.date.issued2022-12
dc.identifier.issn1661-7827
dc.identifier.issn1660-4601
dc.identifier.otherARTN 17095
dc.identifier.urihttp://hdl.handle.net/10026.1/20096
dc.description.abstract

<jats:p>International current best practice recommends the discontinuation of antipsychotics for challenging behaviours in people with intellectual disabilities (ID), due to lack of evidence of efficacy and risks of harmful side-effects. In clinical practice, discontinuation may be difficult. The aim of this study was to gain insight into prescribers’ practice by investigating their experiences with the discontinuation of long-term antipsychotics for challenging behaviour. From professionals’ associations thirty-four registered ID physicians, psychiatrists and specialist mental healthcare nurses were recruited who completed an online questionnaire in this survey–study. Almost all participants had attempted to deprescribe antipsychotics for their patients with ID. Sixty-five percent of participants achieved complete discontinuation in 0–25% of their patients, but none in over 50%. Barriers were a lack of non-pharmaceutical treatments for challenging behaviours and caregivers’ and/or family concern. Seventy percent of participants indicated that their institutions had encouraged implementing their discontinuation policies in line with the new Dutch Act on Involuntary care and a new Dutch multidisciplinary guideline on problem behaviour in adults with ID. Support and facilitation of clinicians from institutions’ managers and political and professional bodies may be helpful in further implementation of best practice in the treatment of challenging behaviour in people with ID.</jats:p>

dc.format.extent17095-17095
dc.format.mediumElectronic
dc.languageen
dc.language.isoen
dc.publisherMDPI AG
dc.subjectintellectual disabilities
dc.subjectantipsychotics
dc.subjectchallenging behaviour
dc.subjectdiscontinuation
dc.subjectprescribers' policies
dc.subjectsurvey
dc.titleWithdrawing Antipsychotics for Challenging Behaviours in Adults with Intellectual Disabilities: Experiences and Views of Prescribers
dc.typejournal-article
dc.typeJournal Article
plymouth.author-urlhttps://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000900727300001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008
plymouth.issue24
plymouth.volume19
plymouth.publication-statusPublished online
plymouth.journalInternational Journal of Environmental Research and Public Health
dc.identifier.doi10.3390/ijerph192417095
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/Users by role
dc.publisher.placeSwitzerland
dcterms.dateAccepted2022-12-15
dc.identifier.eissn1660-4601
dc.rights.embargoperiodNot known
rioxxterms.versionofrecord10.3390/ijerph192417095
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.typeJournal Article/Review


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV